T-cell acute lymphocytical leukemia (T-ALL)
Conditions
Interventions
Experimental group :CCNU+Thiotepa+BU+CY
Sponsors
Hematology Medical Center, Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with T-ALL, male or female, aged >18 years, the disease achieved complete remission or partial remission after induction chemotherapy. 2. Suitable donors with allogeneic HSCT indications and haploid allogeneic transplantation. 3. Other systemic underlying diseases are stable, without progression or recurrence.
Exclusion criteria
Exclusion criteria: 1. There is uncontrolled active infection; 2. Severe respiratory diseases; 3. Severe abnormal liver function; 4. Severe renal impairment, defined as glomerular filtration rate < 40ml/(min·1.73m^2); 5. Clinically significant or uncontrolled heart disease (grade III or IV congestive heart failure); 6. People who are allergic to cetepai or have a severe allergic constitution; 7. Participate in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year overall survival (OS);3-year leukemia-free survival (LFS);Recurrence rate;Transplant-related mortality (TRM);Observation of major transplant complications; | — |
Countries
China
Contacts
Public ContactKong Peiyan
Hematology Medical Center, Second Affiliated Hospital of Army Medical University
Outcome results
None listed